Table 2 Diabetes-related characteristics between group 1 and group 2 at the first-stage revision arthroplasty
Variables | Group 1: HbA1c < 7 (n = 44) | Group 2: HbA1c ≥ 7 (n = 44) | p |
|---|---|---|---|
Diabetes subtype | |||
Type 1 | 0 (0%) | 0 (0%) | 1 |
Type 2 | 44 (100%) | 44 (100%) | |
Duration of Diabetes, years (SD) | 9.59 (5.50) | 11.5 (5.52) | 0.3 |
Fasting glucose, mmol/l (SD) | 152 (60.2) | 300 (145) | < 0.001* |
HbA1c (1st stage), % (SD) | 6.26 (0.539) | 10.1 (1.68) | < 0.001* |
HbA1c (last stage), % (SD) | 6.32 (0.342) | 6.86 (1.10) | 0.116 |
Self-reported drug intake (N, %) | 5.00 (22.7%) | 9.00 (40.9%) | 0.332 |
No glucose-lowering drugs | 2 (4.5%) | 4 (9.1%) | 1 |
Anti-diabetic agent | |||
Metformin | 18 (40.9%) | 26 (59.1%) | 0.366 |
GLP-1 receptor agonist (Liraglutide, dulaglutide, soliqua) | 0 (0%) | 2 (4.5%) | 1 |
SGLT2 inhibitor (Empagliflozin, dapagliflozin, canagliflozin) | 0 (0%) | 2 (4.5%) | 1 |
Sulfonylurea (Glipizide, Glimepiride, Gliclazide) | 8 (18.2%) | 24 (54.5%) | 0.0268* |
Glinides (Mitiglinde, Repaglinide, Nateglinide) | 0 (0%) | 2 (4.5%) | 1 |
TZD (Pioglitazone, Rosiglitazone) | 2 (4.5%) | 2 (4.5%) | 1 |
DPP4 inhibitor (Saxagliptin, Linagliptin, Alogliptin, Vildagliptin) | 2 (4.5%) | 18 (40.9%) | 0.00934* |
Acarbose | 0 (0%) | 12 (27.3%) | 0.0211 |
Insulin only | 0 (0%) | 8 (18.2%) | 0.108 |
Insulin combined with other OAD | 4 (9.1%) | 20 (45.5%) | 0.0157* |
ACE inhibitor or ARB | 4 (9.1%) | 20 (45.5%) | 0.0157* |
Diuretic | 8 (18.2%) | 10 (22.7%) | 1 |
Calcium antagonist | 16 (36.4%) | 20 (45.5%) | 0.759 |
Beta blocker | 10 (22.7%) | 20 (45.5%) | 0.203 |
Other antihypertensive drug | 14 (31.8%) | 14 (31.8%) | 1 |
Any antihypertensive drug | 10 (22.7%) | 8 (18.2%) | 1 |
Statin | 12 (27.3%) | 10 (22.7%) | 1 |
Fibrate | 0 (0%) | 0 (0%) | 1 |
Antiplatelet therapy | 0 (0%) | 4 (9.1%) | 0.488 |
Anti-coagulant | 10 (22.7%) | 12 (27.3%) | 1 |